|
1
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Therapy Evaluation Program (CTEP)
Common Terminology Criteria for Adverse Events (CTCAE). Version
4.0. National Cancer Institute, . 2010.
|
|
3
|
Chouaid C, Dujon C, Do P, Monnet I,
Madroszyk A, Le Caer H, Auliac JB, Berard H, Thomas P, Lena H, et
al: Feasibility and clinical impact of re-biopsy in advanced non
small-cell lung cancer: A prospective multicenter study in a
real-world setting. Lung Cancer. 86:170–173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nosaki K, Satouchi M, Kurata T, Yoshida T,
Okamoto I, Katakami N, Imamura F, Tanaka K, Yamane Y, Yamamoto N,
et al: Re-biopsy status among non-small cell lung cancer patients
in Japan: A retrospective study. Lung Cancer. 101:1–8. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scher KS, Saldivar JS, Fishbein M,
Marchevsky A and Reckamp KL: EGFR-mutated lung cancer with
T790M-acquired resistance in the brain and histologic
transformation in the lung. J Natl Compr Canc Netw. 11:1040–1044.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bugano DDG, Kalhor N, Zhang J, Neskey M
and William WN: Squamous-cell transformation in a patient with lung
adenocarcinoma receiving erlotinib: Co-occurrence with T790M
mutation. Cancer Treat Commun. 4:34–36. 2015. View Article : Google Scholar
|
|
7
|
Burkart J, Shilo K, Zhao W, Ozkan E, Ajam
A and Otterson GA: Metastatic squamous cell carcinoma component
from an adenosquamous carcinoma of the lung with identical
epidermal growth factor receptor mutations. Case Rep Pulmonol.
2015:2838752015.PubMed/NCBI
|
|
8
|
Hsieh MS, Jhuang JY, Hua SF and Chou YH:
Histologic evolution from adenocarcinoma to squamous cell carcinoma
after gefitinib treatment. Ann Thorac Surg. 99:316–319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kuiper JL, Ronden MI, Becker A, Heideman
DA, van Hengel P, Ylstra B, Thunnissen E and Smit EF:
Transformation to a squamous cell carcinoma phenotype of an
EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine
kinase inhibitor. J Clin Pathol. 68:320–321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Levin PA, Mayer M, Hoskin S, Sailors J,
Oliver DH and Gerber DE: Histologic transformation from
adenocarcinoma to squamous cell carcinoma as a mechanism of
resistance to EGFR inhibition. J Thorac Oncol. 10:e86–e88. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jukna A, Montanari G, Mengoli MC, Cavazza
A, Covi M, Barbieri F, Bertolini F and Rossi G: Squamous cell
carcinoma ‘transformation’ concurrent with secondary T790M mutation
in resistant EGFR-mutated adenocarcinomas. J Thorac Oncol.
11:e49–e51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Haratani K, Hayashi H, Watanabe S, Kaneda
H, Yoshida T, Takeda M, Shimizu T and Nakagawa K: Two cases of EGFR
mutation-positive lung adenocarcinoma that transformed into
squamous cell carcinoma: Successful treatment of one case with
rociletinib. Ann Oncol. 27:200–202. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bruno R, Proietti A, Alì G, Puppo G,
Ribechini A, Chella A and Fontanini G: Squamous cell transformation
and EGFR T790M mutation as acquired resistance mechanisms in a
patient with lung adenocarcinoma treated with a tyrosine kinase
inhibitor: A case report. Oncol Lett. 14:5947–5951. 2017.PubMed/NCBI
|
|
14
|
Longo L, Mengoli MC, Bertolini F, Bettelli
S, Manfredini S and Rossi G: Synchronous occurrence of
squamous-cell carcinoma ‘transformation’ and EGFR exon 20 S768I
mutation as a novel mechanism of resistance in EGFR-mutated lung
adenocarcinoma. Lung Cancer. 103:24–26. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Le T, Sailors J, Oliver DH, Mayer M,
Hoskin S and Gerber DE: Histologic transformation of EGFR mutant
lung adenocarcinoma without exposure to EGFR inhibition. Lung
Cancer. 105:14–16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Okabe N, Takagi H, Mine H, Fukai S,
Minemura H and Suzuki H: Osimertinib for epidermal growth factor
receptor mutation-positive lung adenocarcinoma that transformed to
T790M-positive squamous cell carcinoma. J Thorac Oncol.
12:e167–e169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Clery E, Pisapia P, Feliciano S, Vigliar
E, Marano A, De Luca C, Malapelle U, Troncone G and Bellevicine C:
There is still a role for cytology in the ‘liquid biopsy’ era. A
lesson from a TKI-treated patient showing adenocarcinoma to
squamous cell carcinoma transition during disease progression. J
Clin Pathol. 70:798–802. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Izumi H, Yamasaki A, Ueda Y, Sumikawa T,
Maeta H, Nakamoto S and Shimizu E: Squamous cell carcinoma
transformation from EGFR-mutated lung adenocarcinoma: A case report
and literature review. Clin Lung Cancer. 19:e63–e66. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jänne PA, Yang JC, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J
Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shukuya T, Takahashi T, Kaira R, Ono A,
Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Kaira K, Murakami H, et
al: Efficacy of gefitinib for non-adenocarcinoma non-small-cell
lung cancer patients harboring epidermal growth factor receptor
mutations: A pooled analysis of published reports. Cancer Sci.
102:1032–1037. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hou S, Zhou S, Qin Z, Yang L, Han X, Yao S
and Ji H: Evidence, mechanism, and clinical relevance of the
transdifferentiation from lung adenocarcinoma to squamous cell
carcinoma. Am J Pathol. 187:954–962. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 world health organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shimizu J, Oda M, Hayashi Y, Nonomura A
and Watanabe Y: A clinicopathologic study of resected cases of
adenosquamous carcinoma of the lung. Chest. 109:989–994. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gawrychowski J, Bruliński K, Malinowski E
and Papla B: Prognosis and survival after radical resection of
primary adenosquamous lung carcinoma. Eur J Cardiothorac Surg.
27:686–692. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jia XL and Chen G: EGFR and KRAS mutations
in Chinese patients with adenosquamous carcinoma of the lung. Lung
Cancer. 74:396–400. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang R, Pan Y, Li C, Zhang H, Garfield D,
Li Y, Ye T, Hu H, Luo X, Li H, et al: Analysis of major known
driver mutations and prognosis in resected adenosquamous lung
carcinomas. J Thorac Oncol. 9:760–768. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fan L, Yang H, Yao F, Zhao Y, Gu H, Han K
and Zhao H: Clinical outcomes of epidermal growth factor receptor
tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of
the lung after resection. Onco Targets Ther. 10:239–245. 2017.
View Article : Google Scholar : PubMed/NCBI
|
